The 5th U.S. Circuit Court of Appeals issued a unanimous ruling Friday blocking the mailing of mifepristone prescriptions, requiring the abortion medication to be dispensed only in person at clinics — a decision that represents the most significant restriction on abortion access in the United States since the Supreme Court overturned Roe v. Wade in 2022.
The ruling overrides Food and Drug Administration regulations that had allowed mifepristone to be prescribed via telehealth and mailed directly to patients. It applies in all 50 states, including those without existing abortion restrictions.
The case was brought by Louisiana Attorney General Liz Murrill, who sued the FDA last month arguing its regulations allowed out-of-state providers to circumvent Louisiana’s ban on abortions at all stages of pregnancy. Writing for the court, Judge Kyle Duncan, appointed by President Trump, stated that the regulation created an effective mechanism for placing the drug in the hands of Louisiana residents in defiance of state law.
Mifepristone was approved by the FDA in 2000 and has a well-established safety and efficacy record. It is typically used in combination with misoprostol to end early pregnancies. Surveys indicate that medication abortion now accounts for the majority of abortions performed in the United States, and that approximately one in four abortions nationally are prescribed via telehealth. Providers have credited telehealth access with preventing a significant decline in abortion numbers following the fall of Roe.
Mifepristone manufacturer Danco Laboratories has asked the appeals court to pause its order for one week to allow time to seek emergency relief from the U.S. Supreme Court, where the case is widely expected to be appealed. The ruling remains in effect while that process plays out. Legal experts note there is little modern precedent for a federal court overriding the scientific regulatory determinations of the FDA.
The FDA under the Trump administration is currently conducting a new safety review of mifepristone, though the appeals court noted no completion timeline has been established. The FDA and Department of Justice did not immediately respond to requests for comment.
The ruling drew praise from abortion opponents, who called it a victory for life, and sharp criticism from abortion-rights advocates, who characterized it as scientifically unsupported and out of step with public opinion. Some anti-abortion allies of President Trump expressed frustration that his administration had not taken independent action to restrict the pill’s distribution — including through the FDA’s approval last year of a new generic version of mifepristone.
Some Democratic-led states have adopted shield laws designed to protect providers who prescribe and mail abortion pills across state lines. Those laws are currently being tested in civil and criminal proceedings in Louisiana and Texas, and Friday’s ruling adds a new layer of legal complexity to that landscape.
With midterm elections approaching in November, the ruling is expected to elevate abortion access as a central campaign issue. Since Roe was overturned, abortion has appeared on the ballot directly in 17 states, with voters siding with abortion-rights positions in 14 of those contests.
Why This Matters to You
For your wallet, the practical cost implications of this ruling fall most heavily on people who rely on telehealth for affordable access to reproductive healthcare. In-person clinic visits require transportation, time off work, and in many states, travel across significant distances — costs that fall disproportionately on lower-income individuals. If the ruling is upheld, those out-of-pocket costs for patients seeking medication abortion are likely to increase substantially.
In your community, this ruling affects everyone regardless of personal views on abortion. Pharmacies, telehealth platforms, and healthcare providers across all 50 states — including states with no abortion restrictions — will need to adjust how mifepristone is dispensed while the legal process continues. Clinics in states with shield laws are already working with legal counsel to determine what remains permissible. The uncertainty alone is likely to create disruption in how reproductive healthcare is delivered in the near term.
On a personal level, this ruling represents a rare and significant moment in which a federal court has overridden the regulatory determination of the FDA — an agency whose scientific standards govern the safety and availability of every medication Americans take. The implications of that precedent extend well beyond abortion. If upheld, it establishes a legal pathway for courts to intervene in FDA drug approvals and regulations based on political or moral objections rather than scientific evidence — a development with potential consequences for how any number of future medications are regulated and distributed.
-Elijah Iraheta, Editor-in-Chief, ASC News
